Differential binding of human immunoagents and Herceptin to the ErbB2 receptor

FEBS Journal

Volumn 275, Issue 20, 2008, Pages 4967-4979

  Troise, Fulvia ^a   Cafaro, Valeria ^a   Giancola, Concetta ^a   D'Alessio, Giuseppe ^a   De Lorenzo, Claudia ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Binding affinity; ErbB2; Herceptin; ImmunoRNase; Immunotherapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERBICIN; ERBICIN IMMUNOGLOBULIN G1 FC FRAGMENT; ERBICIN RIBONUCLEASE; IMMUNOGLOBULIN FC FRAGMENT; IMMUNOGLOBULIN G1; RIBONUCLEASE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTIBODY ENGINEERING; ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CARDIOTOXICITY; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DOMAIN;

ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; IMMUNOGLOBULIN FRAGMENTS; IMMUNOTHERAPY; PROTEIN BINDING; PROTEIN ENGINEERING; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; TUMOR CELLS, CULTURED;

EID: 52449095375     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/j.1742-4658.2008.06625.x     Document Type: Article

References (32)

1. Yamamoto T, Ikawa S, Akiyama T, Semba K, Nomura N, Miyajima N, Saito T Toyoshima K (1986) Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 319, 230 234.
2. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235, 177 182.
3. Pupa SM, Menard S, Morelli D, Pozzi B, De Palo G Colnaghi MI (1993) The extracellular domain of the c-erbB-2 oncoprotein is released from tumor cells by proteolytic cleavage. Oncogene 8, 2917 2923.
4. Wu JT, Astill ME Zhang P (1993) Detection of the extracellular domain of c-erbB-2 oncoprotein in sera from patients with various carcinomas: correlation with tumor markers. J Clin Lab Anal 7, 31 40.
5. Stebbing J, Copson E O'Reilly S (2000) Herceptin (trastuzamab) in advanced breast cancer. Cancer Treat Rev 26, 287 290.
6. Cardoso F, Piccart MJ, Durbecq V Di Leo A (2002) Resistance to trastuzumab: a necessary evil or a temporary challenge? Clin Breast Cancer 3, 247 257 discussion 258-249.
7. Nahta R Esteva FJ (2006) Herceptin: mechanisms of action and resistance. Cancer Lett 232, 123 138.
8. Chien KR (2000) Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity. Semin Oncol 27, 9 14 discussion 92-100.
9. Sparano JA (2001) Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials. Semin Oncol 28, 20 27.
10. Spiridon CI, Ghetie MA, Uhr J, Marches R, Li JL, Shen GL Vitetta ES (2002) Targeting multiple Her-2 epitopes with monoclonal antibodies results in improved antigrowth activity of a human breast cancer cell line in vitro and in vivo. Clin Cancer Res 8, 1720 1730.
11. Willems A, Gauger K, Henrichs C Harbec N (2005) Antibody therapy for breast cancer. Anticancer Res 25, 1483 1489.
12. De Lorenzo C, Palmer DB, Piccoli R, Ritter MA D'Alessio G (2002) A new human antitumor immunoreagent specific for ErbB2. Clin Cancer Res 8, 1710 1719.
13. De Lorenzo C, Arciello A, Cozzolino R, Palmer DB, Laccetti P, Piccoli R D'Alessio G (2004) A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas. Cancer Res 64, 4870 4874.
14. De Lorenzo C, Tedesco A, Terrazzano G, Cozzolino R, Laccetti P, Piccoli R D'Alessio G (2004) A human, compact, fully functional anti-ErbB2 antibody as a novel antitumour agent. Br J Cancer 91, 1200 1204.
15. De Lorenzo C, Cozzolino R, Carpentieri A, Pucci P, Laccetti P D'Alessio G (2005) Biological properties of a human compact anti-ErbB2 antibody. Carcinogenesis 26, 1890 1895.
16. Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA Ullrich A (1990) Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 50, 1550 1558.
17. De Lorenzo C, Troise F, Cafaro V D'Alessio G (2007) Combinatorial experimental protocols for Erbicin-derived immunoagents and Herceptin. Br J Cancer 97, 1354 1360.
18. de Kruif J, van der Vuurst de Vries AR, Cilenti L, Boel E, van Ewijk W Logtenberg T (1996) New perspectives on recombinant human antibodies. Immunol Today 17, 453 455.
19. Brodowicz T, Wiltschke C, Budinsky AC, Krainer M, Steger GG Zielinski CC (1997) Soluble HER-2/neu neutralizes biologic effects of anti-HER-2/neu antibody on breast cancer cells in vitro. Int J Cancer 73, 875 879.
20. Junghans RP (1999) Cruel antibody fictions! Cellular antigen enumeration by 'saturation' binding. Immunol Today 20, 401 406.
21. Finkelstein MS Uhr JW (1966) Antibody formation. V. The avidity of gamma-M and gamma-G guinea pig antibodies to bacteriophage phi-x 174. J Immunol 97, 565 576.
22. Agnati LF, Genedani S, Leo G, Forni A, Woods AS, Filaferro M, Franco R Fuxe K (2007) Abeta peptides as one of the crucial volume transmission signals in the trophic units and their interactions with homocysteine. Physiological implications and relevance for Alzheimer's. J Neural Transm 114, 21 23.
23. Reynwar BJ, Illya G, Harmandaris VA, Muller MM, Kremer K Deserno M (2007) Aggregation and vesiculation of membrane proteins by curvature-mediated interactions. Nature 447, 461 464.
24. Citri A Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7, 505 516.
25. Clayton AH, Walker F, Orchard SG, Henderson C, Fuchs D, Rothacker J, Nice EC Burgess AW (2005) Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor - a multidimensional microscopy analysis. J Biol Chem 280, 30392 30399.
26. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J et al. (1996) Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 14, 737 744.
27. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA et al. (1998) Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16, 2659 2671.
28. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227, 680 685.
29. Karlsson R, Michaelsson A Mattsson L (1991) Kinetic analysis of monoclonal antibody-antigen interactions with a new biosensor based analytical system. J Immunol Methods 145, 229 240.
30. Steckbeck JD, Grieser HJ, Sturgeon T, Taber R, Chow A, Bruno J, Murphy-Corb M, Montelaro RC Cole KS (2006) Dynamic evolution of antibody populations in a rhesus macaque infected with attenuated simian immunodeficiency virus identified by surface plasmon resonance. J Med Primatol 35, 248 260.
31. Scatchard G (1949) The attractions of proteins for small molecules and ions. Annu NY Acad Sci 51, 660 666.
32. Erra E, Petraccone L, Esposito V, Randazzo A, Mayol L, Ladbury J, Barone G Giancola C (2005) Interaction of porphyrin with G-quadruplex structures. Nucleosides Nucleotides Nucleic Acids 24, 753 756.